Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06119191 · ClinicalTrials.gov registry record · NA
Clinical Evaluation of Reusable Soft Contact Lenses
A NA study of Myopia, sponsored by CooperVision International Limited (CVIL).
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
- 5
- Study locations
NCT06119191: Completed NA study of Myopia, sponsored by CooperVision International Limited (CVIL).
NCT06119191 is a NA study of Myopia that has completed, run by CooperVision International Limited (CVIL). The registered enrollment target is 77 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06119191, a NA study of Myopia, has completed, sponsored by CooperVision International Limited (CVIL).
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study was to confirm the clinical performance of a novel manufacturing process for comfilcon A contact lenses in habitual wearers over a one-month period of lens wear.
Primary Outcome
Monocular distance logMAR visual acuity at distance 4 meters under high illumination, high contrast conditions was measured at the 4 week timepoint of lens wear.
Conditions Studied
Interventions
- DEVICE Control Lenses (comfilcon A with current process)
- DEVICE Test Lenses (comfilcon A with novel process)
Study Locations (5)
Ohio
- Ohio State University College of Optometry - Columbus
- ProCare Vision Center, Inc. - Granville
California
- Clinical Research Center, UC Berkeley - Berkeley
Indiana
- Clinical Optics Research Lab at IU School of Optometry - Bloomington
New York
- SUNY College of Optometry Clinical Vision Research Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2023-11-14 |
| Est. Completion | 2024-03-01 |
| Phase | NA |
What the finished NCT06119191 record still lists
NCT06119191 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Control Lenses (comfilcon A with current process) is the first listed.
NCT06119191 lists 5 locations in 4 states (Ohio, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT06119191 about?
NCT06119191 is a clinical study titled "Clinical Evaluation of Reusable Soft Contact Lenses". The purpose of this study was to confirm the clinical performance of a novel manufacturing process for comfilcon A contact lenses in habitual wearers over a one-month period of lens wear.
What is the current status of trial NCT06119191?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2023-11-14. Estimated completion is 2024-03-01.
What conditions does trial NCT06119191 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT06119191?
The interventions under investigation include: Control Lenses (comfilcon A with current process) (DEVICE), Test Lenses (comfilcon A with novel process) (DEVICE).
Who is sponsoring clinical trial NCT06119191?
This trial is sponsored by CooperVision International Limited (CVIL), which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06119191 being conducted?
This trial has 5 study locations across California, Indiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06119191's enrollment target sits among peer trials
77 48th of 90 higher than 43 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI